From XE-2100 to XN-9000, from SIS Standard to GFHC recommendations for slide review: potential impact on review rate and turnaround time.
In 2014, we moved from XE-2100 with Standard SIS rules to XN-9000 with GFHC recommendations for slide review. The aim of our study was to evaluate the potential impact of the new Sysmex® automation with implementation of GFHC rules on our review rate, turnaround time (TAT), workload and on CD34+ stem cells enumeration. We conducted a retrospective observational study from September 2013 through August 2014, in CHU Dinant Godinne UCL Namur. With the GFHC recommendations and the new Sysmex® automation, we significantly reduced our review rate by nearly 30% considering all units (35.8% vs 25.9%), and up to 73% when excluding oncology haematology department (17.5% vs 4.7%). We also noticed significantly shorter TAT for CBC measurement (median for routine samples: 76.4 vs 56.8 minutes, p < 0.0001; urgent samples: 18.9 vs 15.2 minutes, p = 0.023), slide review (median: 54.9 vs 36.4 minutes, p < 0.0001) and CD34+ enumeration performed on peripheral blood samples (p < 0.001) and on apheresis samples (p = 0.026). In conclusion, GFHC recommendations implemented on the new Sysmex® XN-9000 resulted in a significant reduction in review rate and in TAT. This is particularly of interest for the clinicians with subsequent potential faster patient management.